A new treatment for cancer has produced favourable results in its first trials on patients.
British Biotech, of Cowley, studied data from 23 people who used medication designed to selectively kill small lung cancer cells. Doctors found that tumours were reduced or stabilised in four patients.
Later this year a second study will start, when patients will be given the drug more frequently.
The firm paid Immogen £1m for the European and Japanese drug rights.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article